Alexander Drzezga studied human medicine at the Ludwig Maximilians University and the Technical University of Munich, obtained a license for medical practice, and took up residency at the Department of Nuclear Medicine of the Technical University of Munich.
In 2002 Drzezga specialized in nuclear medicine, and was a Consultant at the Department before becoming Assistant Professor at the Technical University. Since 2012 he has been Professor and Chair of the Department of nuclear medicine at the University Hospital Cologne, and he is currently the chair of the Department of Nuclear Medicine at the University Hospital Cologne and affiliated with the German Center for Neurodegenerative Disorders (DZNE) and the Institute for Neuroscience and Medicine (INM) at the Research Center Juelich. In 2018 he became Director at the INM.
Drzezga’s research focus is on the application of multimodal and molecular imaging procedures to investigate neurodegenerative disorders and their interrelation to the network architecture of the brain. He is a member of the AMYPAD project and is a Principal Investigator at the AMYPAD site in Cologne, Germany.
Alexander Drzezga has received grant funding and research support from, Sofie, Novartis/AAA, and Deutsche Forschungsgesellschaft, DFG, BMBF, Juelich, Wellcome Leap, Bayer Vital, European Research Council, Invicros, Biogen, GE Healthcare; and honoraria or consulting fees from GE Healthcare, Biogen, Novartis, Lilly, Siemens Healthineers, Springer Healthcare, Lilly Deutschland, Peer View Institute for Medical Education Inc., Bayer Vital GmbH, Invicro, and International Atomic Energy Agency, Swiss Rockets.
He holds Stocks, shares or equity in Siemens Healthineers, Lantheus Holding, Structured Therapeutics, Lilly. In addition he has applied for patent for 2-Alkoxy-6-[18F]Fluoronicotinoyl substituted Lys-C(O)-Glu derivatives as efficient probes for imaging of PSMA expressing tissues (Patent No.: EP3765097A1).
He has received other financial or material support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, Eisai, Sofie, Ariceum Therapeutics, AVID.
